Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in
addition to best supportive care is effective in prolonging the lives of subjects with
unresectable stage III non-small cell lung cancer, compared to best supportive care alone.
A local ancillary (sub) study in European centers will evaluate the immune response in
peripheral blood after tecemotide (L-BLP25) or placebo vaccination.